This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Bergapten
DrugBank Accession Number
DB12216
Background

Bergapten is under investigation in clinical trial NCT00533195 (Comparison of UVA1 Phototherapy Versus Photochemotherapy for Patients With Severe Generalized Atopic Dermatitis).

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 216.192
Monoisotopic: 216.042258738
Chemical Formula
C12H8O4
Synonyms
  • 5 methoxypsoralen
  • 5-methoxypsoralen
External IDs
  • NSC-95437

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetohexamideThe therapeutic efficacy of Acetohexamide can be increased when used in combination with Bergapten.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be increased when used in combination with Bergapten.
DexmethylphenidateThe serum concentration of the active metabolites of Bergapten can be increased when Bergapten is used in combination with Dexmethylphenidate.
GliclazideThe therapeutic efficacy of Gliclazide can be increased when used in combination with Bergapten.
GlimepirideThe therapeutic efficacy of Glimepiride can be increased when used in combination with Bergapten.
GlipizideThe therapeutic efficacy of Glipizide can be increased when used in combination with Bergapten.
GliquidoneThe therapeutic efficacy of Gliquidone can be increased when used in combination with Bergapten.
GlyburideThe therapeutic efficacy of Glyburide can be increased when used in combination with Bergapten.
LepirudinThe risk or severity of bleeding can be increased when Bergapten is combined with Lepirudin.
PadeliporfinBergapten may increase the photosensitizing activities of Padeliporfin.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

ATC Codes
D05BA03 — Bergapten
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as 5-methoxypsoralens. These are psoralens containing a methoxy group attached at the C5 position of the psoralen group.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Coumarins and derivatives
Sub Class
Furanocoumarins
Direct Parent
5-methoxypsoralens
Alternative Parents
1-benzopyrans / Benzofurans / Anisoles / Pyranones and derivatives / Alkyl aryl ethers / Heteroaromatic compounds / Furans / Lactones / Oxacyclic compounds / Organic oxides
show 1 more
Substituents
1-benzopyran / 5-methoxypsoralen / Alkyl aryl ether / Anisole / Aromatic heteropolycyclic compound / Benzenoid / Benzofuran / Benzopyran / Ether / Furan
show 10 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organic heterotricyclic compound, psoralens, 5-methoxyfurocoumarin (CHEBI:18293) / Furanocoumarins (C01557) / a coumarin (5-METHOXYFURANOCOUMARIN)
Affected organisms
Not Available

Chemical Identifiers

UNII
4FVK84C92X
CAS number
484-20-8
InChI Key
BGEBZHIAGXMEMV-UHFFFAOYSA-N
InChI
InChI=1S/C12H8O4/c1-14-12-7-2-3-11(13)16-10(7)6-9-8(12)4-5-15-9/h2-6H,1H3
IUPAC Name
4-methoxy-7H-furo[3,2-g]chromen-7-one
SMILES
COC1=C2C=CC(=O)OC2=CC2=C1C=CO2

References

General References
Not Available
Human Metabolome Database
HMDB0030637
KEGG Compound
C01557
PubChem Compound
2355
PubChem Substance
347828496
ChemSpider
2265
BindingDB
50067880
RxNav
15842
ChEBI
18293
ChEMBL
CHEMBL24171
ZINC
ZINC000000057731
Wikipedia
Bergapten

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentAtopic Dermatitis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.148 mg/mLALOGPS
logP2.12ALOGPS
logP1.78ChemAxon
logS-3.2ALOGPS
pKa (Strongest Basic)-2.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area48.67 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity56.85 m3·mol-1ChemAxon
Polarizability20.87 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-01b9-3890000000-a8341e87fa6830843ef7
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-00y1-3940000000-1492cacf3f4395e9f66c
Mass Spectrum (Electron Ionization)MSsplash10-01b9-7950000000-e77dc647c2fa0ccbb177
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-014i-0090000000-af65171e5fbd0d0f2f8d
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-014i-0190000000-f11609a8b07550b0255d
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0pic-1930000000-6fadbe89a5a3974a8f95
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-014i-0190000000-7d80d6ed97043f207cf4
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-014i-0590000000-1f47d1bdb75386655f1f
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4j-0900000000-38a514b1687da9023de8
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0090000000-927b1385246a4f40d60d
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0uxr-0090000000-53c9077581fc1617f789
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0290000000-d6eb013ef1071457a5b1
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0gb9-0090000000-c9f12dbc22ea5656f07c
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0uxr-0190000000-7a948782b86b2057690c
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0190000000-e8c8dc33e2d74b5af54a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0190000000-8bc360c878c7ddfb2135
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0090000000-d0dd8082e47d3cdf89c8
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0390000000-b51bcbe48eab7eb99e0f
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-01b9-0900000000-187f429d7e359302ca69
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0udi-0950000000-b19407bde306a78efe77
1H NMR Spectrum1D NMRNot Applicable

Drug created at October 20, 2016 21:38 / Updated at June 12, 2020 16:53